LAUNXP Biomedical Co., Ltd (TPEX:6876)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
22.10
+0.30 (1.38%)
Apr 20, 2026, 1:24 PM CST
Market Cap707.51M +28.9%
Revenuen/a
Net Incomen/a
EPSn/a
Shares Out32.45M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1
Average Volume285,467
Open22.00
Previous Close21.80
Day's Range21.90 - 23.00
52-Week Range16.30 - 27.00
Beta0.06
RSI45.87
Earnings Daten/a

About LAUNXP Biomedical

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6876
Full Company Profile